The rapid rise of private equity’s influence over health care providers such as hospitals, nursing homes, and physicians’ ...

This analysis reviews the history and current status of biosimilar regulation in the US, concluding that changing the FDA’s interchangeability standards—as proposed by some policy makers—is a ...